Compare Funko Inc (FNKO) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Funko Inc trades at $6.31 (market cap $355.57M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 20.7× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FNKO | SYRE | |
|---|---|---|
Market Cap | $355.57M | $7.35B |
Volume | 738,460 | 1,624,631 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $108.92 |
52-Week Low | $2.81 | $22.18 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $576.22M | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Funko (FNKO) trades at $6.52, up 0.93% with a bullish technical outlook supported by moving averages. The company shows improving fundamentals with Q2 2026 earnings beating expectations, revenue growth of 7% to $207.7M, and raised EBITDA guidance to $105M. Despite negative net margins, the stock trades at attractive valuations with P/S of 0.39x and EV/EBITDA of 6.84x. Recent management changes and product expansions signal strategic momentum.
FNKO presents a turnaround opportunity with improving operational metrics and positive analyst sentiment, though risks remain from inconsistent profitability and high debt levels. The consensus price target of $7.58 suggests 16% upside potential, supported by strong Q2 results and raised guidance. Investors should weigh the company's progress against ongoing margin pressures and competitive challenges in the collectibles market.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
